150 related articles for article (PubMed ID: 9161781)
1. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study.
Dutcher JP; Fisher RI; Weiss G; Aronson F; Margolin K; Louie A; Mier J; Caliendo G; Sosman JA; Eckardt JR; Ernest ML; Doroshow J; Atkins M
Cancer J Sci Am; 1997; 3(3):157-62. PubMed ID: 9161781
[TBL] [Abstract][Full Text] [Related]
2. Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II study.
Stoter G; Shiloni E; Aamdal S; Cleton FJ; Iacobelli S; Bijman JT; Palmer P; Franks CR; Rodenhuis S
Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S41-3. PubMed ID: 2697578
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma.
Whitehead RP; Ward D; Hemingway L; Hemstreet GP; Bradley E; Konrad M
Cancer Res; 1990 Oct; 50(20):6708-15. PubMed ID: 2208137
[TBL] [Abstract][Full Text] [Related]
4. Recombinant interferon alpha-2 (INTRON A) in a phase II study of renal cell carcinoma.
Kempf RA; Grunberg SM; Daniels JR; Skinner DG; Venturi CL; Spiegel R; Neri R; Greiner JM; Rudnick S; Mitchell MS
J Biol Response Mod; 1986 Feb; 5(1):27-35. PubMed ID: 3958753
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study.
Negrier S; Philip T; Stoter G; Fossa SD; Janssen S; Iacone A; Cleton FS; Eremin O; Israel L; Jasmin C
Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S21-8. PubMed ID: 2697575
[TBL] [Abstract][Full Text] [Related]
6. Combination of interleukin-2 and interferon-alpha in renal cell carcinoma and malignant melanoma: a phase II clinical trial.
Veelken H; Rosenthal FM; Schneller F; von Schilling C; Guettler IC; Herrmann F; Mertelsmann R; Lindemann A
Biotechnol Ther; 1992; 3(1-2):1-14. PubMed ID: 1305889
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
Budd GT; Osgood B; Barna B; Boyett JM; Finke J; Medendorp SV; Murthy S; Novak C; Sergi J; Tubbs R
Cancer Res; 1989 Nov; 49(22):6432-6. PubMed ID: 2804986
[TBL] [Abstract][Full Text] [Related]
8. Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study.
Atzpodien J; Körfer A; Evers P; Franks CR; Knüver-Hopf J; Lopez-Hänninen E; Fischer M; Mohr H; Dallmann I; Hadam M
Mol Biother; 1990 Mar; 2(1):18-26. PubMed ID: 2334534
[TBL] [Abstract][Full Text] [Related]
9. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma.
Atzpodien J; Lopez Hänninen E; Kirchner H; Bodenstein H; Pfreundschuh M; Rebmann U; Metzner B; Illiger HJ; Jakse G; Niesel T
J Clin Oncol; 1995 Feb; 13(2):497-501. PubMed ID: 7844611
[TBL] [Abstract][Full Text] [Related]
10. Recombinant interferon-alpha 2a and vinblastine in advanced renal cell cancer: a clinical phase I-II study.
Kellokumpu-Lehtinen P; Nordman E
J Biol Response Mod; 1990 Aug; 9(4):439-44. PubMed ID: 2395008
[TBL] [Abstract][Full Text] [Related]
11. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.
Figlin RA; Belldegrun A; Moldawer N; Zeffren J; deKernion J
J Clin Oncol; 1992 Mar; 10(3):414-21. PubMed ID: 1482425
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: a Southwest Oncology Group study.
Bukowski RM; Goodman P; Crawford ED; Sergi JS; Redman BG; Whitehead RP
J Natl Cancer Inst; 1990 Jan; 82(2):143-6. PubMed ID: 2294224
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of recombinant interferon alpha-2C in metastatic renal cell carcinoma.
Scheithauer W; Kuehrer I; Kutzmits R; Dittrich C; Steger G; Flener R; Ludwig H
J Biol Regul Homeost Agents; 1987; 1(2):81-6. PubMed ID: 3504086
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal cell cancer: the German outpatient experience.
Kirchner H; Körfer A; Palmer PA; Evers P; De Riese W; Knüver-Hopf J; Hadam M; Goldman U; Franks CR; Poliwoda H
Mol Biother; 1990 Sep; 2(3):145-54. PubMed ID: 2222898
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of combination therapy with interleukin 2 and beta-interferon in patients with advanced malignancy.
Tamura T; Sasaki Y; Shinkai T; Eguchi K; Sakurai M; Fujiwara Y; Nakagawa K; Minato K; Bungo M; Saijo N
Cancer Res; 1989 Feb; 49(3):730-5. PubMed ID: 2783385
[TBL] [Abstract][Full Text] [Related]
16. Treatment of renal cell carcinoma with alpha (human leukocyte) interferon and vinblastine in combination: a phase I-II trial.
Figlin RA; deKernion JB; Maldazys J; Sarna G
Cancer Treat Rep; 1985 Mar; 69(3):263-7. PubMed ID: 3978656
[TBL] [Abstract][Full Text] [Related]
17. Clinical application of continuous infusion of recombinant interleukin-2.
West WH
Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S11-5. PubMed ID: 2627985
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer.
Marincola FM; White DE; Wise AP; Rosenberg SA
J Clin Oncol; 1995 May; 13(5):1110-22. PubMed ID: 7738617
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.
Budd GT; Murthy S; Finke J; Sergi J; Gibson V; Medendorp S; Barna B; Boyett J; Bukowski RM
J Clin Oncol; 1992 May; 10(5):804-9. PubMed ID: 1569452
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of alpha 2-interferon plus doxorubicin in patients with solid tumors.
Sarosy GA; Brown TD; Von Hoff DD; Spiegel RJ; Golando JP; Beougher KL; Kuhn JG; Kisner DL
Cancer Res; 1986 Oct; 46(10):5368-71. PubMed ID: 3756887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
